SG11201502074YA - Novel inhibitor compounds of phosphodiesterase type 10a - Google Patents
Novel inhibitor compounds of phosphodiesterase type 10aInfo
- Publication number
- SG11201502074YA SG11201502074YA SG11201502074YA SG11201502074YA SG11201502074YA SG 11201502074Y A SG11201502074Y A SG 11201502074YA SG 11201502074Y A SG11201502074Y A SG 11201502074YA SG 11201502074Y A SG11201502074Y A SG 11201502074YA SG 11201502074Y A SG11201502074Y A SG 11201502074YA
- Authority
- SG
- Singapore
- Prior art keywords
- inhibitor compounds
- phosphodiesterase type
- novel inhibitor
- novel
- phosphodiesterase
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D495/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
- C07D513/14—Ortho-condensed systems
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261702005P | 2012-09-17 | 2012-09-17 | |
| US201261702371P | 2012-09-18 | 2012-09-18 | |
| PCT/EP2013/069173 WO2014041175A1 (en) | 2012-09-17 | 2013-09-16 | Novel inhibitor compounds of phosphodiesterase type 10a |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201502074YA true SG11201502074YA (en) | 2015-05-28 |
Family
ID=49226152
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201502074YA SG11201502074YA (en) | 2012-09-17 | 2013-09-16 | Novel inhibitor compounds of phosphodiesterase type 10a |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US9388180B2 (en) |
| EP (1) | EP2895489B1 (en) |
| JP (1) | JP2015528484A (en) |
| KR (1) | KR20150056844A (en) |
| CN (1) | CN105102461A (en) |
| AR (1) | AR092595A1 (en) |
| AU (1) | AU2013314244A1 (en) |
| BR (1) | BR112015005935A2 (en) |
| CA (1) | CA2883910A1 (en) |
| HK (1) | HK1206728A1 (en) |
| IL (1) | IL237626A0 (en) |
| IN (1) | IN2015DN01900A (en) |
| MX (1) | MX2015003419A (en) |
| RU (1) | RU2015114331A (en) |
| SG (1) | SG11201502074YA (en) |
| TW (1) | TW201418264A (en) |
| UY (1) | UY35036A (en) |
| WO (1) | WO2014041175A1 (en) |
| ZA (1) | ZA201501458B (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112015004427A2 (en) | 2012-10-26 | 2017-07-04 | Hoffmann La Roche | compounds, methods for treating an inflammatory condition, rheumatoid arthritis, asthma, an immune disorder and an immune disorder and pharmaceutical composition |
| US9840553B2 (en) | 2014-06-28 | 2017-12-12 | Kodiak Sciences Inc. | Dual PDGF/VEGF antagonists |
| US11066465B2 (en) | 2015-12-30 | 2021-07-20 | Kodiak Sciences Inc. | Antibodies and conjugates thereof |
| CN111592495A (en) * | 2020-07-06 | 2020-08-28 | 上海启讯医药科技有限公司 | Preparation method of 2-n-butyl-4-chloro-5-formylimidazole |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030032579A1 (en) | 2001-04-20 | 2003-02-13 | Pfizer Inc. | Therapeutic use of selective PDE10 inhibitors |
| US7057042B2 (en) * | 2002-05-29 | 2006-06-06 | Abbott Laboratories | Fused bicyclic aromatic compounds that are useful in treating sexual dysfunction |
| US20070032404A1 (en) | 2003-07-31 | 2007-02-08 | Bayer Pharmaceuticals Corporation | Methods for treating diabetes and related disorders using pde10a inhibitors |
| CA2568929A1 (en) | 2004-06-07 | 2005-12-22 | Pfizer Products Inc. | Phosphodiesterase 10 inhibition as treatment for obesity-related and metabolic syndrome-related conditions |
| CA2578996A1 (en) | 2004-09-03 | 2006-03-16 | Memory Pharmaceuticals Corporation | 4-substituted 4, 6-dialkoxy-cinnoline derivatives as phospodiesterase 10 inhibitors for the treatment of psychiatric or neurological syndroms |
| AP2007003923A0 (en) * | 2004-09-30 | 2007-02-28 | Tibotec Pharm Ltd | Hcv inhibiting bi-cyclic pyrimidines |
| MX2008002207A (en) | 2005-08-16 | 2008-03-27 | Memory Pharm Corp | Phosphodiesterase 10 inhibitors. |
| NL2000397C2 (en) | 2006-01-05 | 2007-10-30 | Pfizer Prod Inc | Bicyclic heteroaryl compounds as PDE10 inhibitors. |
| WO2007082546A1 (en) | 2006-01-20 | 2007-07-26 | H. Lundbeck A/S | Use of tofisopam as a pde10a inhibitor |
| BRPI0707223A2 (en) | 2006-01-27 | 2011-04-26 | Pfizer Prod Inc | aminophthalazine derivative compounds |
| WO2007098214A1 (en) | 2006-02-21 | 2007-08-30 | Amgen Inc. | Cinnoline derivatives as phosphodiesterase 10 inhibitors |
| CA2643963A1 (en) | 2006-02-21 | 2007-08-30 | Amgen Inc. | Cinnoline derivatives as phosphodiesterase 10 inhibitors |
| CA2641670A1 (en) | 2006-02-23 | 2007-08-30 | Pfizer Products Inc. | Substituted quinazolines as pde10 inhibitors |
| CA2643044A1 (en) | 2006-02-28 | 2007-09-07 | Amgen Inc. | Cinnoline and quinazoline derivates as phosphodiesterase 10 inhibitors |
| US20070265258A1 (en) | 2006-03-06 | 2007-11-15 | Ruiping Liu | Quinazoline derivatives as phosphodiesterase 10 inhibitors |
| MX2008011257A (en) | 2006-03-08 | 2008-09-25 | Amgen Inc | Quinoline and isoquinoline derivatives as phosphodiesterase 10 inhibitors. |
| TW200817400A (en) | 2006-05-30 | 2008-04-16 | Elbion Ag | Pyrido [3,2-e] pyrazines, their use as inhibitors of phosphodiesterase 10, and processes for preparing them |
| TW200815436A (en) | 2006-05-30 | 2008-04-01 | Elbion Ag | 4-amino-pyrido[3,2-e]pyrazines, their use as inhibitors of phosphodiesterase 10, and processes for preparing them |
| WO2008001182A1 (en) | 2006-06-26 | 2008-01-03 | Pfizer Products Inc. | Tricyclic heteroaryl compounds as pde10 inhibitors |
| US20080090834A1 (en) | 2006-07-06 | 2008-04-17 | Pfizer Inc | Selective azole pde10a inhibitor compounds |
| SI2057153T1 (en) | 2006-07-10 | 2012-12-31 | H. Lundbeck A/S | (3-aryl-piperazin-1-yl) derivatives of 6,7-dialkoxyquinazoline, 6,7- dialkoxyphtalazine and 6,7-dialkoxyisoquinoline |
| WO2008020302A2 (en) | 2006-08-17 | 2008-02-21 | Pfizer Products Inc. | Heteroaromatic quinoline-based compounds as phosphodiesterase (pde) inhibitors |
| WO2009025823A1 (en) | 2007-08-21 | 2009-02-26 | Amgen Inc. | Phosphodiesterase 10 inhibitors |
| WO2009025839A2 (en) | 2007-08-22 | 2009-02-26 | Amgen Inc. | Phosphodiesterase 10 inhibitors |
| WO2009029214A1 (en) | 2007-08-23 | 2009-03-05 | Amgen Inc. | Isoquinolone derivatives as phosphodiesterase 10 inhibitors |
| TW200918519A (en) | 2007-09-19 | 2009-05-01 | Lundbeck & Co As H | Cyanoisoquinoline |
| CN101918408A (en) * | 2007-11-30 | 2010-12-15 | 惠氏有限责任公司 | Aryl and heteroaryl fused imidazo[1,5-a]pyrazines as inhibitors of phosphodiesterase 10 |
| US20090143361A1 (en) | 2007-11-30 | 2009-06-04 | Elbion Gmbh | Pyrido[3,2-E]Pyrazines, Process For Preparing The Same, And Their Use As Inhibitors Of Phosphodiesterase 10 |
| CA2706986A1 (en) | 2007-11-30 | 2009-06-04 | Elbion Gmbh | Aryl and heteroaryl fused imidazo (1,5-a) pyrazines as inhibitors of phosphodiesterase 10 |
| WO2009068246A2 (en) | 2007-11-30 | 2009-06-04 | Elbion Gmbh | Methods of treating obesity and metabolic disorders |
| RU2545023C9 (en) | 2008-06-10 | 2016-06-20 | Эббви Инк. | Tricyclic compounds, pharmaceutical composition containing them and using them for treating immunological and oncological compounds |
| US20100120763A1 (en) * | 2008-11-07 | 2010-05-13 | Wyeth | Imidazo[5,1-c][1,2,4]benzotriazine derivatives as inhibitors of phosphodiesterases |
| WO2011008597A1 (en) | 2009-07-14 | 2011-01-20 | Schering Corporation | Dihydroimidazoisoquinoline derivatives useful as pde10 inhibitors |
| US8361962B2 (en) | 2009-07-27 | 2013-01-29 | Roche Palo Alto Llc | Tricyclic inhibitors of JAK |
-
2013
- 2013-09-16 CA CA2883910A patent/CA2883910A1/en not_active Abandoned
- 2013-09-16 SG SG11201502074YA patent/SG11201502074YA/en unknown
- 2013-09-16 BR BR112015005935A patent/BR112015005935A2/en not_active IP Right Cessation
- 2013-09-16 JP JP2015531593A patent/JP2015528484A/en not_active Withdrawn
- 2013-09-16 WO PCT/EP2013/069173 patent/WO2014041175A1/en active Application Filing
- 2013-09-16 EP EP13765695.5A patent/EP2895489B1/en not_active Not-in-force
- 2013-09-16 MX MX2015003419A patent/MX2015003419A/en unknown
- 2013-09-16 AU AU2013314244A patent/AU2013314244A1/en not_active Abandoned
- 2013-09-16 CN CN201380048224.3A patent/CN105102461A/en active Pending
- 2013-09-16 RU RU2015114331A patent/RU2015114331A/en not_active Application Discontinuation
- 2013-09-16 IN IN1900DEN2015 patent/IN2015DN01900A/en unknown
- 2013-09-16 KR KR1020157009897A patent/KR20150056844A/en not_active Application Discontinuation
- 2013-09-17 AR ARP130103326A patent/AR092595A1/en unknown
- 2013-09-17 US US14/029,142 patent/US9388180B2/en active Active
- 2013-09-17 UY UY0001035036A patent/UY35036A/en not_active Application Discontinuation
- 2013-09-17 TW TW102133710A patent/TW201418264A/en unknown
-
2015
- 2015-03-03 ZA ZA2015/01458A patent/ZA201501458B/en unknown
- 2015-03-09 IL IL237626A patent/IL237626A0/en unknown
- 2015-07-28 HK HK15107215.7A patent/HK1206728A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20140107126A1 (en) | 2014-04-17 |
| KR20150056844A (en) | 2015-05-27 |
| AU2013314244A1 (en) | 2015-03-12 |
| ZA201501458B (en) | 2018-11-28 |
| EP2895489A1 (en) | 2015-07-22 |
| TW201418264A (en) | 2014-05-16 |
| MX2015003419A (en) | 2015-09-23 |
| WO2014041175A1 (en) | 2014-03-20 |
| AU2013314244A8 (en) | 2015-04-30 |
| EP2895489B1 (en) | 2017-10-18 |
| AR092595A1 (en) | 2015-04-29 |
| BR112015005935A2 (en) | 2017-07-04 |
| IL237626A0 (en) | 2015-04-30 |
| CN105102461A (en) | 2015-11-25 |
| JP2015528484A (en) | 2015-09-28 |
| UY35036A (en) | 2014-03-31 |
| RU2015114331A (en) | 2016-11-10 |
| IN2015DN01900A (en) | 2015-08-07 |
| US9388180B2 (en) | 2016-07-12 |
| HK1206728A1 (en) | 2016-01-15 |
| CA2883910A1 (en) | 2014-03-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL263262B (en) | Compounds useful as inhibitors of atr kinase | |
| SG10201605196PA (en) | Novel Inhibitor Compounds Of Phosphodiesterase Type 10A | |
| HK1215253A1 (en) | Pyrrolopyrimidine compounds as kinase inhibitors | |
| HK1201519A1 (en) | Inhibitors of phosphodiesterase type 10a 10a | |
| HK1211921A1 (en) | Inhibitor compounds | |
| HK1211942A1 (en) | Pyrazolopyrimidine compounds as kinase inhibitors | |
| HK1210178A1 (en) | Substituted pyridopyrazines as syk inhibitors syk | |
| HK1219273A1 (en) | Novel inhibitor compounds of phosphodiesterase type 10a 10a | |
| HK1211024A1 (en) | Inhibitors of syk syk | |
| HK1206728A1 (en) | Novel inhibitor compounds of phosphodiesterase type 10a 10a | |
| PL2888228T3 (en) | Inhibitors of cd40-traf6 interaction | |
| HK1211581A1 (en) | Novel inhibitor compounds of phosphodiesterase type 10a 10a | |
| GB201211019D0 (en) | Inhibitor compounds | |
| PT2784068E (en) | Phosphodiesterase 4 inhibitor capable of avoiding vomiting | |
| HK1211284A1 (en) | Inhibitor compounds of phosphodiesterase type 10a 10a |